KRKavitha Ramaswamy

Kavitha Ramaswamy

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kavitha Ramaswamy has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The Impact of v‐SYMPHONY's Virtual Boot Camp on Trainee Transition From Residency to Fellowship

    by Anshul Vagrecha, Adit L. Tal, Kayleen A. Bailey, Andrea D. Orsey, Danielle Cohen, Jessica E. Briggs, Jeremy Rosenblum, Farzana Pashankar, Katharine Offer, Alexander J. Chou, et al.

    Background: Starting a pediatric subspecialty fellowship presents numerous challenges to trainees. Virtual Symposium of Pediatric Hematology/Oncology of New York (v‐SYMPHONY), an educational collaborative organized by 18 pediatric hematology–oncology (PHO) programs, initiated an annual bootcamp in 2022 aimed at easing the transition from pediatric residency to PHO fellowship. Methods: The bootcamp consisted of virtual clinical lectures and fellow‐led panels, which were created with input from diverse program leadership, educators, and past fellows using Kern's six‐step module of curriculum development. It was offered to incoming fellows, first in the NY/NJ/CT region, and subsequently expanded nationally. Results: Over 4 years (2022–2025), 147 pediatric residents completed this virtual bootcamp. The number of residents attending the live sessions increased from 19 in 2022 to 62 in 2025. Forty‐four participants completed pre‐ and post‐bootcamp surveys over this period, which showed significant improvement in both self‐reported medical knowledge and preparedness and reported a decrease in transition to fellowship anxiety scores. Conclusion: These results highlight the need and benefits of a standardized orientation program that can be delivered virtually to ease the transition of PHO trainees from residency to fellowship. Such a standardized curriculum is feasible, adaptable, and potentially scalable to a national level.

  • Open Access

    Outcomes of Adolescents and Young Adults with AML Treated on Pediatric vs Adult Protocols

    by Baher Krayem, Jeetayu Biswas, Andriy Derkach, Michael Rafizadeh, Jenna R Ciervo, Christopher A. Famulare, Omar Abdel-Wahab, Neerav N. Shukla, Tanya Trippett, Christopher Jon Forlenza, et al.

    Adolescents and young adults (AYA) with acute myeloid leukemia (AML) represent a biologically and clinically distinct population managed across pediatric and adult oncology services, with no established optimal treatment paradigm. In this single-center retrospective study, we analyzed 81 AYA patients aged 14-29 years with newly diagnosed AML treated at Memorial Sloan Kettering Cancer Center between 2010 and 2025. Patients were stratified by treating service, European LeukemiaNet (ELN) 2022 risk category, and induction regimen. Pediatric patients received two cycles of cytarabine, daunorubicin, and etoposide (ADE)-based induction, while adult patients received one cycle of cytarabine plus daunorubicin (7+3) induction-three of whom required 7+3 reinduction-followed by risk-adapted consolidation including allogeneic hematopoietic stem cell transplantation. Composite complete response rates were similar between adult and pediatric cohorts (79% vs. 78%), as were rates of MRD negativity by multicolor flow cytometry among responders (63% vs. 55%). Despite comparable depth of response, five-year overall survival favored adult-service patients in both the full cohort (77.9% vs. 56.7%) and the ELN 2022 intermediate-adverse risk subgroup (62.7% vs. 47.9%), while relapse-free survival was nearly identical. On multivariable analysis, ELN 2022 risk retained independent prognostic significance, whereas treatment protocol did not. These findings demonstrate that pediatric-style and adult AML regimens achieve comparable remission depth in AYA patients. The survival advantage observed with adult protocols challenges the assumption that further cytotoxic intensification improves outcomes in this population.

  • Open Access

    Clofarabine with topotecan, vinorelbine, and thiotepa reinduction regimen for children and young adults with relapsed AML

    by Kavitha Ramaswamy, Peter G. Steinherz, Anurag K. Agrawal, Christopher Jon Forlenza, Audrey Mauguen, Mikhail Roshal, Tanya Trippett, Nancy A. Kernan, Maria Luisa Sulis, Neerav Narendra Shukla

    Effective reinduction regimens are needed for children with relapsed and refractory acute myeloid leukemia (AML), as outcomes remain poor. Therapeutic options are limited in this heavily pretreated patient population, many of whom have reached lifetime recommended doses of anthracycline chemotherapy. The development of effective non-anthracycline–based salvage regimens is crucial to these patients who are at significant risk of life-threatening cardiotoxicity. We previously reported results of a phase 2 trial of a clofarabine-based regimen with topotecan, vinorelbine, and thiotepa (TVTC) in patients with relapsed acute leukemias. Here we report on an expanded bicenter cohort of 33 patients, <25 years of age, with relapsed/refractory AML treated with up to 2 cycles of the TVTC reinduction regimen from 2007 to 2018. The overall response rate, defined as complete remission or complete remission with partial recovery of platelet count, was 71.4% (95% confidence interval [CI], 41.9-91.6) for those patients in first relapse (n = 14) and 47.4% (95% CI, 24.4-71.1) for patients in second or greater relapse or with refractory disease. Responses were seen across multiple high-risk cytogenetic and molecular subtypes, with 84% of responders successfully bridged to allogeneic stem cell transplantation. The 5-year overall survival for patients in first relapse was 46.2% (95% CI, 19.1-73.3) and 50.0% (95% CI, 26.9-73.1) for patients who responded to TVTC. For pediatric and young adult patients with relapsed/refractory AML, TVTC reinduction compares favorably with currently used salvage regimens and warrants further exploration.


  • Open Access

    Impact of Bridging Chemotherapy on Clinical Outcomes of CD19-Specific CAR T Cell Therapy in Children/Young Adults with Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia

    by Sanam Shahid, Kavitha Ramaswamy, Jessica Flynn, Audrey Mauguen, Karlo Perica, Jae H. Park, Christopher J. Forlenza, Neerav N. Shukla, Peter G. Steinherz, Steven P. Margossian, et al.


  • Open Access

    Bridging Chemotherapy Prior to CD19-Specific CAR T Cell Therapy in Children/Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia

    by Sanam Shahid, Kavitha Ramaswamy, Jessica Flynn, Audrey Mauguen, Karlo Perica, Jae H Park, Kevin J Curran